• Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently
Read more at globenewswire.comPolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here